Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study

Bevacizumab has provided encouraging results in relapsed glioblastoma multiforme (GBM). Pre-clinical and clinical investigations also showed that continuous low-dose temozolomide has some antiangiogenic activity. Based on this evidence, a phase II trial was designed to investigate an oral regimen of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer research 2013-08, Vol.33 (8), p.3487
Hauptverfasser:	Zustovich, Fable, Landi, Lorenza, Lombardi, Giuseppe, Porta, Camillo, Galli, Luca, Fontana, Andrea, Amoroso, Domenico, Galli, Costanza, Andreuccetti, Michele, Falcone, Alfredo, Zagonel, Vittorina
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Brain Neoplasms - drug therapy Dacarbazine - administration & dosage Dacarbazine - adverse effects Dacarbazine - analogs & derivatives Dacarbazine - therapeutic use Disease Progression Dose-Response Relationship, Drug Drug Administration Schedule Female Glioblastoma - drug therapy Humans Magnetic Resonance Imaging Male Middle Aged Niacinamide - administration & dosage Niacinamide - adverse effects Niacinamide - analogs & derivatives Niacinamide - therapeutic use Phenylurea Compounds - administration & dosage Phenylurea Compounds - adverse effects Phenylurea Compounds - therapeutic use Recurrence Survival Analysis Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!